Mikko Niemi

Mikko Niemi

  • PL 20 (Tukholmankatu 8 C)

    00014

    Finland

20002021

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Curriculum vitae

1. Personal details and date of CV

Niemi, Mikko Olavi (male)

ORCID iD: 0000-0003-4550-2189, ResearcherID A-1088-2008

Year of birth: 1975, Nationality: Finnish        

https://www.helsinki.fi/en/faculty-of-medicine/research/research-programs-unit/individualized-drug-therapy-individrug

Date of CV 10.2.2021

2. Degrees

2010, Medical Specialist, Clinical Pharmacology and Pharmacotherapy, University of Helsinki, Finland

2004, Title of Docent, Clinical Drug Research, University of Helsinki, Finland    

2002, Doctor of Medical Sciences (PhD), Faculty of Medicine, University of Helsinki, Finland

2000, Licentiate of Medicine (MD), Faculty of Medicine, University of Helsinki, Finland

3. Current employment

Since 2010, Professor, Pharmacogenetics, University of Helsinki, Finland      

Since 2011, Chief Physician (secondary occupation), HUS Diagnostic Center, Helsinki University Hospital, Finland

4. Previous work experience

2009-2010, Acting Clinical Lecturer, Department of Clinical Pharmacology, University of Helsinki, Finland (5 mo)

2009, Acting Professor and Chief Physician of Pharmacogenetics, Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Hospital (10 mo)                             

2003-2004, Alexander von Humboldt Foundation post-doctoral fellowship, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (17 mo)

1998-2009, Various positions as a researcher, specializing physician or general practitioner at the University of Helsinki and various health care organizations in Finland

5. Career breaks

none

6. Research funding and grants (as principal investigator)

Competitive research funding from:

Helsinki University Hospital State funding for university-level health research

Sigrid Jusélius Foundation

University of Helsinki

Cancer Society of Finland

Academy of Finland

European Research Council (ERC Starting Grant 2012, Consolidator Grant 2017)

Total amount: 7 300 000 €.

7. Research output

129 original articles, 20 reviews and 4 letters in international peer-reviewed journals, 11 articles or reviews and 4 editorials in national professional journals, 10 book chapters. One granted patent (FI 125478 B)

Publications and citations: https://scholar.google.com/citations?user=QInuBUAAAAAJ&hl=fi&oi=ao

8. Research supervision and leadership experience

Supervised 5 postdoctoral researchers, 6 completed doctoral theses, and 4 master’s theses. Currently supervising 3 postdoctoral researchers and 12 doctoral students.

Since 2019, Director, Individualized Drug Therapy Research Program, University of Helsinki

2015-2017, Director, Doctoral Program in Biomedicine, University of Helsinki

Since 2015, Member of the Steering Committee, MD/PhD program, University of Helsinki

9. Teaching merits

Since 2000 involved in clinical pharmacology curriculum planning and teaching at the University of Helsinki. Organized and lectured in several post-graduate courses and undergraduate programs in several universities. 10 ECTS University pedagogics training 2010-11.

10. Awards and honours

2017, Orion Research Foundation Award

2015, Leon I. Goldberg Young Investigator Award, American Society for Clinical Pharmacology and Therapeutics

2014-, Highly Cited Researcher (Pharmacology & Toxicology), Thomson Reuters/Clarivate Analytics

2014, Invited member of the Finnish Academy of Science and Letters

2014, Distinguished Adjunct Professor, King Abdulaziz University, Jeddah, Saudi Arabia

2010, Anders Jahre Prize for Young Scientists, University of Oslo

2009, Young investigator award, Finnish Medical Society Duodecim

2001, Best doctoral thesis award, Finnish Society of Clinical Pharmacology

11. Other key academic merits

Reviewer for 11 doctoral dissertations

Opponent of 7 doctoral dissertations

Memberships and positions of trust in scientific organisations: Pharmacogenomics Research Network 2020-, European Society of Pharmacogenomics and Personalized Therapy 2019- (board member 2020-), American Society for Clinical Pharmacology and Therapeutics 2010-, International Transporter Consortium 2008-, International Society for the Study of Xenobiotics 2008, Finnish Pharmacological Society 2001-, Finnish Medical Society Duodecim 2000-, Finnish Society of Clinical Pharmacology 2000- (secretary 2010-2014, chair 2014-2018, board member 2019-).

Memberships in expert, evaluation or steering groups and other expert roles: since 2019, Member of the steering group, Biobank Helsinki; since 2016, Chair, Scientific and ethical review committee, Biobank Helsinki

Editorial board memberships: Human genomics 2020-, Clinical Pharmacology & Therapeutics 2015-2019, Physiological Genomics 2015-, Basic & Clinical Pharmacology &Toxicology 2011-, European Journal of Clinical Pharmacology 2010-2014, Pharmacogenomics 2008-, Pharmacogenetics & Genomics 2007-.

>50 invited presentations in international congresses

>10 invited presentations in foreign research institutes

Experience of organising scientific meetings:

2019, Chair of the organising committee, Pharmacogenetics at the University of Helsinki 10 Year Anniversary Symposium – from Discovery to Clinical Implementation, Helsinki, Finland, ~140 participants

2018, Member of the organising committee, Improving Rational Pharmacotherapy – 50 Years of Clinical Pharmacology in Finland, Helsinki, Finland, ~60 participants

2014, Member of the international scientific advisory board and session chair, 20th International Symposium on Microsomes and Drug Oxidations, Germany

2012, Member of the international scientific advisory board and session chair, 19th MDO and 12th European ISSX Meeting, The Netherlands

2011, Chair of the organising committee, Personalized Drug Therapy Symposium, Finland, ~180 participants

12. Scientific and societal impact

Key positions of trust, expert positions and assignments:

Since 2016, Member of the Board of Trustees, Finnish Cultural Foundation

Since 2016, Member of Finnish Genome Center Working Group, Ministry of Social Affairs and Health, Finland

2016-2020, Permanent expert, National authority for medicolegal affairs

Since 2015, Member of National Implementation of EU Regulation on Clinical Trials Working Group, Ministry of Social Affairs and Health, Finland

2011-2015, Member of the steering committee, HUSLAB, Helsinki University Hospital

2010, Member of Pharmaceutical Policy 2020 Working Group, Ministry of Social Affairs and Health, Finland

2009-2017, Member of the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa

Frequent interviews in newspapers, radio and television news and current affairs programs.

 

Fields of Science

  • 3111 Biomedicine
  • 3121 General medicine, internal medicine and other clinical medicine
  • Clinical pharmacology and Pharmacotherapy
  • 318 Medical biotechnology
  • Pharmacogenetics

International and National Collaboration

Publications and projects within past five years.